Co-Diagnostics, Inc.
CODX Nasdaq
SEC CIK 1692415
Follow Co-Diagnostics
Weekly email: filings, results
Revenue, last quarter
$282.9K
+94.6% vs same quarter last year
Net income
−$6.3M
−7.1% vs same quarter last year
EPS, diluted
−$1.01
+78.3% vs same quarter last year
Operating cash flow
−$5.7M
+3.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $622.5K | −$47M |
| FY24 | $3.9M | −$38M |
| FY23 | $6.8M | −$35.3M |
| FY22 | $34.2M | −$14.2M |
| FY21 | $97.9M | $36.7M |
| FY20 | $74.6M | $42.5M |
| FY19 | $215K | −$6.2M |
| FY18 | $39.9K | −$6.3M |
| FY17 | $7.7K | −$7M |
| FY16 | - | −$1.9M |
| FY15 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 64.3% | −8058.8% | −7550.3% |
| FY24 | 74.5% | −1023.7% | −970.6% |
| FY23 | 38.6% | −626.9% | −518.7% |
| FY22 | 84% | −78.8% | −41.6% |
| FY21 | 88.2% | 47.1% | 37.5% |
| FY20 | 77.7% | 55.9% | 57% |
| FY19 | 47.7% | −2741.6% | −2882% |
| FY18 | 76.5% | −15328.6% | −15714.3% |
| FY17 | 96.1% | −59567.6% | −90827.9% |
| FY16 | - | - | - |
| FY15 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$29.8M |
| FY24 | −$29.9M |
| FY23 | −$23.4M |
| FY22 | $5.1M |
| FY21 | $40.4M |
| FY20 | $27.4M |
| FY19 | −$5.6M |
| FY18 | −$4.1M |
| FY17 | −$3.3M |
| FY16 | −$1.3M |
| FY15 | - |
- Co-Diagnostics
- Healthcare median
Show the numbers
| Year | Co-Diagnostics | Healthcare median |
|---|---|---|
| FY25 | −7550.3% | −30.6% |
| FY24 | −970.6% | −47% |
| FY23 | −518.7% | −58% |
| FY22 | −41.6% | −80.4% |
| FY21 | 37.5% | −71.8% |
| FY20 | 57% | −62.2% |
| FY19 | −2882% | −46.2% |
| FY18 | −15714.3% | −49.6% |
| FY17 | −90827.9% | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −37.8% |